Published in Vaccine Weekly, March 30th, 2005
According to recent research from New Zealand, "Dendritic cell (DC)-based vaccination represents a promising approach to harness the specificity and potency of the immune system to combat cancer. Finding optimal strategies for tumor antigen preparation and subsequent pulsing of DC, as well as improving the immunogenicity of weak tumor antigens remain among the first challenges of this approach. In this report, we use a prophylactic vaccine consisting of DC loaded with whole, non-manipulated B16-F10 melanoma cells that had been...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.